Affimed is actualizing the untapped potential of the innate immune system. Leveraging our modular and versatile ROCK® (Redirected Optimized Cell Killing) platform, we generate proprietary, next-generation bispecific antibodies. Our tetravalent (four binding sites) bispecific (two targets) immune cell engagers have the ability to bring NK cells or T cells into proximity to cancer cells and trigger a signal cascade that leads to the destruction these cancer cells. A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy. Lead pipeline candidates include AFM13 (CD16A/CD30 in CD30+ve lymphomas) in Ph 2, AFM24 (CD16A/EGFR) targeting IND in mid-2019, and AFM11 (CD3/CD19) in Ph 1. Affimed also has a target-based research collaboration with Roche/Genentech to discover and develop novel innate cell engagers.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):